SCHEMBL4947692

SCHEMBL4947692

CCCCCN1CCCCC1C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.50
CYP3A4 P08684 1/20 0.50
CYP2D6 P10635 1/20 0.50
KCNH2 Q12809 1/20 0.50
POLB P06746 1/20 0.50
TSHR P16473 1/20 0.50
NR1I2 O75469 1/20 0.46
S1PR1 P21453 3/20 0.46
S1PR3 Q99500 3/20 0.46
S1PR5 Q9H228 3/20 0.46
S1PR4 O95977 1/20 0.44
KCNK3 O14649 1/20 0.44
LMNA P02545 1/20 0.44
SLC6A1 P30531 2/20 0.43
OPRD1 P41143 1/20 0.42
L3MBTL1 Q9Y468 2/20 0.40
BCHE P06276 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7114915 1.00 SMN1; SMN2 (0.50) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL7114016 1.00 SMN1; SMN2 (0.50) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL5509944 0.98 SMN1; SMN2 (0.49) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL20210387 0.98 SMN1; SMN2 (0.49) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL10623312 0.98 SMN1; SMN2 (0.49) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL3442998 0.95 SMN1; SMN2 (0.54) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL13975748 0.95 SMN1; SMN2 (0.54) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL9093440 0.95 SMN1; SMN2 (0.54) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL1381895 0.95 NR1I2 (0.50) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB
SCHEMBL1381896 0.95 NR1I2 (0.50) SMN1; SMN2CYP3A4CYP2D6KCNH2POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0784603-B1 RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF DARWIN DISCOVERY LTD (GB) 2003-04-23 EP claimed
US-6156900-A Racemization of precursors to levobupivacaine and analogues thereof DARWIN DISCOVERY LIMITED (GB) 2000-12-05 US claimed
EP-0723586-B1 ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID DARWIN DISCOVERY LTD (GB) 1999-12-22 EP claimed
US-5733754-A ACYLASE WHICH HYDROLYZING N-ACETYLPIPECOLIC ACID CHIROSCIENCE LIMITED (GB) 1998-03-31 US claimed
EP-0784603-A2 RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF Chiroscience Limited (GB) 1997-07-23 EP claimed
EP-0723586-A1 ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID Chiroscience Limited (GB) 1996-07-31 EP claimed
WO-1996011173-A2 RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF CHIROSCIENCE LIMITED (GB) 1996-04-18 WO claimed
WO-1995010604-A1 ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID CHIROSCIENCE LIMITED (GB) 1995-04-20 WO claimed
US-11987590-B2 Compounds that participate in cooperative binding and uses thereof Revolution Medicines, Inc. (US) 2024-05-21 US disclosed
WO-2024102421-A2 COMPOUNDS, COMPLEXES, AND METHODS FOR THEIR PREPARATION AND OF THEIR USE Revolution Medicines, Inc. (US) 2024-05-16 WO disclosed
EP-4289950-A2 MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF Revolution Medicines, Inc. (US) 2023-12-13 EP disclosed
EP-4242304-A2 METHODS AND REAGENTS FOR ANALYZING PROTEIN-PROTEIN INTERFACES Warp Drive Bio, Inc. (US) 2023-09-13 EP disclosed
EP-3247378-B1 MACROCYCLIC COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND MEDICAL USES THEREOF WARP DRIVE BIO INC (US) 2023-07-19 EP disclosed
US-20220144849-A1 COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2022-05-12 US disclosed
EP-0784603-A2 RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF Chiroscience Limited (GB) 1997-07-23 EP disclosed
EP-0723586-A1 ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID Chiroscience Limited (GB) 1996-07-31 EP disclosed
EP-0719779-A1 SUBSTITUTED THIAZOLO [3,2-ALPHA]AZEPINE DERIVATIVE Eisai Co., Ltd. (JP) 1996-07-03 EP disclosed
WO-1996011173-A2 RACEMISATION OF PRECURSORS TO LEVOBUPIVACAINE AND ANALOGUES THEREOF CHIROSCIENCE LIMITED (GB) 1996-04-18 WO disclosed
WO-1995010604-A1 ENZYME AND ITS USE IN PREPARING (S)-PIPECOLIC ACID CHIROSCIENCE LIMITED (GB) 1995-04-20 WO disclosed
CN-1076928-A 1-[2-arylsulfonyl amino)-and the 1-oxoethyl] piperidine derivative and preparation and the application in treatment SYNTHELABO (FR) 1993-10-06 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220144849-A1 COMPOUNDS THAT PARTICIPATE IN COOPERATIVE BINDING AND USES THEREOF CEP170, PIN1, FKBP3 SMN1; SMN2 4805/4885CYP3A4 2870/4885CYP2D6 3819/4885
US-11987590-B2 Compounds that participate in cooperative binding and uses thereof CEP170, PIN1, FKBP3 SMN1; SMN2 4805/4885CYP3A4 2870/4885CYP2D6 3819/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.